Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Real World Results of Multiple Myeloma Patients - Low Mortality Rate from First-Line to Second-Line Treatment

Felix Keil, Petra Attalla, Adelheid Seebacher, Sabine Burger, Elisabeth Koller, Thamer Sliwa, Claudia Laschan, Andreas Krauter, Michael Pfeilstöcker, Michael Fillitz

Blood (2022) 140 (Supplement 1): 12598–12599.

https://doi.org/10.1182/blood-2022-157969

Published: 2022

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Felix Keil, Antonia Maria Susanne Müller, Andrea Berghold, Veronika Buxhofer-Ausch, Judith Schuster, Regina Riedl, Corinne Vorburger, Alexandra Boehm, Michael Panny, Thomas Noesslinger, Richard Greil, Panagiotis Samaras, Thomas Pabst

Blood (2022) 140 (Supplement 1): 1180–1182.

https://doi.org/10.1182/blood-2022-157917

Published: 2022

Journal Articles

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Blood (2022) 140 (Supplement 1): 1346–1349.

https://doi.org/10.1182/blood-2022-168521

Published: 2022

Journal Articles

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Blood (2021) 138 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2021-145401

Published: 2021

Journal Articles

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Blood (2021) 137 (2): 238–247.

https://doi.org/10.1182/blood.2020006157

Published: 2021

Includes: Supplemental data

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Blood (2020) 136 (Supplement 1): 53.

https://doi.org/10.1182/blood-2020-140477

Published: 2020

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Felix Keil, MD, Lisa Obenaus, BSc, Victor Rathkolb, MD, Michael Leiner, MD, Robert Spörk, MSc, Elisabeth Koller, MD, Ernst Forjan, MD, Ralph Simanek, MD, Michael Panny, MD, Daniel Lechner, MD, Alexandra Böhm, MD, Anabel Schönmetzler, MD, Theresia Kornberger, MD, Thomas Noesslinger, MD

Blood (2019) 134 (Supplement_1): 5458.

https://doi.org/10.1182/blood-2019-122024

Published: 2019

Journal Articles

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Thomas Reiter, MD, Marlies Antlanger, Alexandra Böhm, Wolfgang Lamm, Max Gornicec, Ella Willenbacher, MD, David Nachbauer, Werner Rabitsch, Daniel Lechner, MD, Hildegard Greinix, Felix Keil, MD, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5424.

https://doi.org/10.1182/blood.V130.Suppl_1.5424.5424

Published: 2017

Journal Articles

Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation

Blood (2016) 128 (22): 3189.

https://doi.org/10.1182/blood.V128.22.3189.3189

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Thomas Noesslinger, MD, Michael Panny, MD, Michaela Moestl, MD, Elisabeth Koller, MD, Felix Keil, MD

Blood (2016) 128 (22): 2265.

https://doi.org/10.1182/blood.V128.22.2265.2265

Published: 2016

Journal Articles

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

Michael Panny, MD, Katharina Troppan, MD, Peter Neumeister, MD, Thomas Nösslinger, MD, Felix Keil, MD

Blood (2016) 128 (22): 5413.

https://doi.org/10.1182/blood.V128.22.5413.5413

Published: 2016

Journal Articles

High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis

Blood (2016) 128 (22): 5503.

https://doi.org/10.1182/blood.V128.22.5503.5503

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Thomas Noesslinger, MD, Michaela Moestl, MD, Christoph Tinchon, MD, Elisabeth Koller, MD, Werner Linkesch, Univ. Prof, MD, Felix Keil, MD

Blood (2014) 124 (21): 3982.

https://doi.org/10.1182/blood.V124.21.3982.3982

Published: 2014

Journal Articles

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Blood (2013) 122 (21): 851.

https://doi.org/10.1182/blood.V122.21.851.851

Published: 2013

Journal Articles

Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial

Michael A. Fridrik, MD, Andreas L Petzer, M.D., Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jaeger, MD, Alois Lang, MD, Sonja Burgstaller, MD, Johannes Andel, MD, Otto Krieger, M.D., Wilhelm Oberaigner, Richard Greil, MD

Blood (2011) 118 (21): 2676.

https://doi.org/10.1182/blood.V118.21.2676.2676

Published: 2011

Journal Articles

5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML),

Heidrun Karlic, PhD, Rene Reitermaier, Viviane Ghanim, MD, Harald Herrmann, MD, Roman Thaler, M.Sc. PhD, Silvia Spitzer, Franz Varga, PhD, Irina Sadovnik, M.Sc., Katharina Blatt, M.Sc., Felix Keil, MD, Peter Valent, M.D., Michael Pfeilstöcker, MD

Blood (2011) 118 (21): 3463.

https://doi.org/10.1182/blood.V118.21.3463.3463

Published: 2011

NARROW

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Real World Results of Multiple Myeloma Patients - Low Mortality Rate from First-Line to Second-Line Treatment

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine - a Prospective Cohort Study By the AGMT

Peripheral Blood Complete Remission Provides Added Value to the Classical Definition of Morphologic Complete Remission - a Prospective Cohort Study of 1441 Patients with MDS, CMML and AML Treated within the Austrian Azacitidine Registry

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation

Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Treatment of High Risk Aggressive B Cell Lymphomas with DA EPOCH R- a Retrospective Analysis

High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis

Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Rituximab Maintenance Significantly Prolongs Event Free (EFS) and Progression Free Survival (PFS) In Male Patients With Aggressive B-Cell Lymphoma In The NHL13 Study

Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial

5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only